# Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)

> **NCT06060652** · — · UNKNOWN · sponsor: **Centro di Riferimento Oncologico - Aviano** · enrollment: 104 (estimated)

## Conditions studied

- Oligometastatic Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06060652
- **Lead sponsor:** Centro di Riferimento Oncologico - Aviano
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-11
- **Primary completion:** 2026-05-11
- **Final completion:** 2026-05-11
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06060652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06060652, "Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06060652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*